



WEINGARTEN, SCHURGIN, GAGNEBIN & HAYES LLP  
 Ten Post Office Square  
 Boston, Massachusetts 02109  
 Telephone: (617) 542-2290  
 Telecopier: (617) 451-0313

Application No.: 09/550,103  
 Filed: April 14, 2000  
 Group Art Unit: 1647

1647  
 RECEIVED  
 AUG 28 2001  
 TECH CENTER 1600/2900

BOX SEQUENCE  
 COMMISSIONER FOR PATENTS  
 Washington, D.C. 20231

Date: August 22, 2001

Attorney  
 Docket No.: NU-431AX

Sir:

In re application of: Richard C. Deth

Entitled: METHODS IDENTIFYING AND DETERMINING THE EFFECTIVENESS OF THERAPEUTIC PROCESSES  
 OR AGENTS FOR THE TREATMENT OF SCHIZOPHRENIA AND RELATED DISORDERS

Transmitted herewith is an **amendment** in the above-identified application. The following checked items are applicable:

- ☐ This is a Request for Continued Examination under §1.114; a check in the amount of \_\_\_\_\_ is enclosed per §1.17(e).
- ☒ A Petition for Extension of Time for 1 month is hereby made under §1.136(a); a check in the amount of \$55.00 is enclosed per §1.17.
- ☒ In the event a Petition for Extension of Time is required by this paper and not otherwise provided, such Petition is hereby made and authorization is provided herewith to charge Deposit Account No. 23-0804 for the cost of such extension.

☐ \_\_\_\_\_ is hereby appointed Associate Attorney by:  
 Registration No.:

08/27/2001 SSESHE1 00000081 09550103

01 FC:215

55.00 0P

Attorney of Record:

Registration No.:

☒ Other: Sequence Submission Letter including CRF and Paper copy of Sequence Listing.

CLAIMS AFTER AMENDMENT:	MINUS PRIOR PAID CLAIMS:	EQUALS PRESENT EXTRA CLAIMS:	RATE:	ADDITIONAL FEE:
Independent	-0- - -0-	= -0-	x \$80.00 =	-0-
Total	-0- - -0-	= -0-	x \$18.00 =	-0-
<input type="checkbox"/> Multiple Dependent Claims (1st presentation)			+ \$270.00 =	-0-
SUBTOTAL ADDITIONAL FEE				-0-
Small Entity filing, divide by 2. Small Entity status must be asserted.				-0-
TOTAL ADDITIONAL FEE				-0-

☐ No additional fee. ☐ The fee has been calculated above; a check in the amount of \_\_\_\_\_ is enclosed.

☒ The Commissioner is hereby authorized to charge payment of any additional filing fees under §1.16 associated with this communication or credit any overpayment to Deposit Account No. 23-0804.

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to: Box Sequence, Commissioner for Patents, Washington, D.C. 20231 on Aug. 22, 2001.

SUBMIT IN TRIPLICATE  
 HCH/raw 257017-1

Holliday C. Heine  
 Attorney of Record: Holliday C. Heine, Ph.D.  
 Registration No.: 34,346



UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/558.103

04/14/00

DETH

R

NU-431AX

HM22/0622  
WEINGARTEN SCHURGIN GAGNEBIN & HAYES LLP  
TEN POST OFFICE SQUARE  
BOSTON MA 02109

EXAMINER

TURNER, S

ART UNIT

PAPER NUMBER

1647

DATE MAILED:

06/22/01

By RECEIVED

JUN 25 2001

WEINGARTEN, SCHURGIN,  
GAGNEBIN & HAYES

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

**COPY**



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/550,103			

EXAMINER	
ART UNIT	PAPER NUMBER
	2

RECEIVED  
AUG 28 2001  
TECH CENTER 1600/2900

Please find below a communication from the EXAMINER in charge of this application

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. See Figure 1, which contains an amino acid sequence.

APPLICANT IS GIVEN 30 days FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Saoud whose telephone number is (703) 305-7519. If the examiner cannot be reached, inquiries can be directed to Supervisory Patent Examiner Gary Kunz whose telephone number is (703) 308-4623. The fax number for the organization where this application or proceeding is assigned is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

June 21, 2001

CHRISTINE J. SAOUD  
PRIMARY EXAMINER

*Christine J. Saoud*

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: \_\_\_\_\_

**Applicant Must Provide:**

- ☒ An *initial* or substitute **computer readable form (CRF) copy** of the "Sequence Listing".
- ☒ An *initial* or substitute **paper copy** of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A **statement** that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY**